# EDGAR Filing Document

**Accession Number:** 0001658247
**File Stem:** 0001193125-26-011872
**Filing Date:** 2026-1
**Character Count:** 32871
**Document Hash:** e64bc64c0f56af5d6d4b4686afac19c7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-011872.hdr.sgml**: 20260113

**ACCESSION NUMBER**: 0001193125-26-011872

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 31

**CONFORMED PERIOD OF REPORT**: 20260113

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260113

**DATE AS OF CHANGE**: 20260113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Crinetics Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001658247
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 263744114
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38583
- **FILM NUMBER:** 26530729

**BUSINESS ADDRESS:**
- **STREET 1:** 6055 LUSK BLVD.
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-450-6464

**MAIL ADDRESS:**
- **STREET 1:** 6055 LUSK BLVD.
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 13, 2026

## Crinetics Pharmaceuticals, Inc.

#### (Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38583** | **26-3744114** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File**<br> **Number)** | **(IRS Employer<br>Identification No.)** |
| **6055 Lusk Boulevard** | | |
| **San Diego, California** |  | **92121** |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (858) 450-6464

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, par value $0.001 per share | CRNX | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.**  |

---

On January 13, 2026, Crinetics Pharmaceuticals, Inc. (the "Company" or "Crinetics") reiterated certain previously announced preliminary and unaudited financial and operating results for the fourth quarter ended December 31, 2025, including that Crinetics expects to report that it generated net product revenue from PALSONIFY<sup>TM</sup> (paltusotine) of over $5.0 million for the three months ended December 31, 2025.

Crinetics' audited financial statements for the year ended December 31, 2025 are not yet available. Accordingly, this estimate of the Company's net product revenue from PALSONIFY is preliminary and unaudited, and remains subject to completion of the Company's financial closing procedures, including the completion of management's review and related internal controls over financial reporting. Accordingly, the estimated net product revenue from PALSONIFY set forth above reflects the Company's preliminary and unaudited estimate with respect to such information based on information currently available to management, and may differ materially from the Company's actual financial results as of December 31, 2025.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.**  |

---

On January 13, 2026 at 9:45 a.m. Pacific Time, Scott Struthers, Ph.D., Founder and Chief Executive Officer of the Company, presented a Company update at the 44th annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12-15, 2026. A live audio webcast of Dr. Struthers' presentation may be accessed on the Events & Presentations section of the Company's website. During the presentation, the Company referenced the corporate slide presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

The information contained in this report, including the information included in Items 2.02 and 7.01, as well as in Exhibit 99.1 hereto, is being "furnished" and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Securities Act"), is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act or the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except as shall be expressly set forth by specific reference in such a filing.

#### Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical facts contained in this report are forward-looking statements, including statements regarding Crinetics' plans, objectives and expectations (financial and otherwise), including with respect to its 2025 financial and operating results; our ability to effectively commercialize PALSONIFY (paltusotine) to become a market leader or a "blockbuster"; our estimates relating to market size, or our ability to drive diagnosis and treatment for undiagnosed patients; the plans and timelines for approval of paltusotine outside the US; the plans and timelines for a Phase 3 program, regulatory filings or approval of paltusotine for carcinoid syndrome, for atumelnant for CAH and for atumelnant for ACTH-dependent Cushing's syndrome; the ability of atumelnant to transform CAH treatment or to become a "blockbuster" therapy for CAH; the ability of CRN09682 to become a "blockbuster" for neuroendocrine tumors or other SST2+ tumors; the plans and timelines for the clinical development of Crinetics' drug candidates, including the therapeutic potential and clinical benefits or safety profile thereof; the expected timing for the initiation of clinical trials or the potential benefits of our development candidates in patients across multiple indications; the expected timing of additional research pipeline updates or the expected timing of the advancement of those programs; and the expected timing through which Crinetics; cash, cash equivalents, and short-term investments will fund Crinetics' operating plans or its operating cash burn guidance. These forward-looking statements speak only as of the date of this report and are subject to a number of risks, uncertainties and assumptions, including, without limitation, the data available at the time of data analysis; estimates relating to market size and growth potential, which involve a number of assumptions and limitations, particularly about any projections, assumptions, and estimates of our future performance; the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk; the possibility of unfavorable new clinical data and further analyses of existing clinical data; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; our dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of our clinical trials and nonclinical studies; regulatory developments or political changes, policies related to pricing and pharmaceutical drug reimbursement in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy

------

of our product candidates that may limit their development, regulatory approval and/or commercialization; our ability to obtain and maintain intellectual property protection for our product candidates; we may use our capital resources sooner than we expect or our cash burn rate may accelerate; and the other risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading "Risk Factors" in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended September 30, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | [Corporate Slide Presentation](d804277dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | Crinetics Pharmaceuticals, Inc. |
| Date: January 13, 2026 | By: | /s/ R. Scott Struthers, Ph.D. |
|  |  | R. Scott Struthers, Ph.D. <br>President and Chief Executive Officer <br>(Principal Executive Officer) |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g804277g01a01.jpg)

JANUARY 2026 Beyond Building Innovation the Premier to Impact: Endocrinology Business J.P. Morgan Healthcare Conference Angela

------

![LOGO](g804277g02a02.jpg)

Forward Looking Statements and Legal Disclaimers Forward Looking Statements: This contained presentation in this presentation contains forward-looking are forward-looking statements. statements. Crinetics Such Pharmaceuticals, forward-looking Inc. statements ("Crinetics," include, the "company," but are not "we," limited "us," or to, "our") statements cautions regarding: you that our all statements ability to effectively other than commercialize statements of PALSONIFY historical facts (paltusotine) to the become US; the a plans market and leader timelines or a for "blockbuster"; a Phase 3 program, our estimates regulatory relating filings to market or approval size, of or paltusotine our ability to for drive carcinoid diagnosis syndrome, and treatment for atumelnant for undiagnosed for CAH and patients; for atumelnant the plans for and ACTH-dependent timelines approval Cushing's of paltusotine syndrome; outside the ability timelines of atumelnant for the clinical to transform development CAH of treatment our drug candidates, or to become including a "blockbuster" the therapeutic therapy potential for CAH; the and ability clinical of benefits CRN09682 or safety to become profile a "blockbuster" thereof; and the for expected neuroendocrine timing for tumors the initiation or other SST2+ of clinical tumors; trials the or the plans potential and benefits expected of timing our development through which candidates our cash, in cash patients equivalents, across multiple and short-term indications; investments the expected will fund timing our of operating additional plans research or its pipeline operating updates cash burn or the guidance. expected In timing some cases, of the you advancement can identify of forward-looking those programs; statements and the by "potential," terms such "target," as "may," "vision" "believe," or other "anticipate," similar terms "could," or the "should," negatives "estimate," thereof. "expect," "intend," "plan," "project," "will," "contemplate," "predict," "continue," "forecast," "aspire," "lead to," "designed to," "goal," "aim," These achievements statements to be speak materially only as different of the date from of any this future presentation, results, performance involve known or and achievements unknown risks, expressed uncertainties, or implied assumptions, by the forward-looking and other important statements, factors including, that may without cause limitation: our actual the results, data performance available at the or time of data performance; analysis; estimates the future relating performance to market of the size markets and growth in which potential, we operate which are involve necessarily a number subject of assumptions to a high degree and limitations, of uncertainty particularly and risk; about the possibility any projections, of unfavorable assumptions, new clinical and estimates data and of further our future analyses of existing manufacturing, clinical data; research potential and preclinical delays in the and commencement, clinical testing; the enrollment success of and our completion clinical trials of and clinical nonclinical trials and studies; the reporting regulatory of data developments therefrom; or our political dependence changes, on policies third parties related in to connection pricing and with pharmaceutical product drug reimbursement commercialization; in the our United ability States to obtain and and foreign maintain countries; intellectual unexpected property adverse protection side effects for our or product inadequate candidates; efficacy we of may our product use our candidates capital resources that may sooner limit than their we development, expect or our regulatory cash burn approval rate may and/or accelerate; and other uncertainties, risks described some of under which the cannot heading be predicted "Risk Factors" or quantified in documents and some we file of from which time are to beyond time with our control, the Securities you should and Exchange not rely on Commission. these forward-looking Because forward-looking statements as predictions statements of are future inherently events. subject The events to risks and and circumstances statements are reflected qualified in in our their forward-looking entirety by this statements cautionary statement, may not be which achieved is made or occur under and the actual safe harbor results could provisions differ of materially the Private from Securities those projected Litigation in Reform the forward-looking Act of 1995 and, statements. except as required All forward-looking by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Legal Disclaimers: This financial presentation closing procedures, contains a preliminary including the and completion unaudited of estimate management's of our net reviews product and revenue related from internal PALSONIFY controls over as of financial December reporting. 31, 2025. Accordingly, This preliminary such and amount unaudited reflects estimate our preliminary remains and subject unaudited to completion estimate of with our respect to such information, based on information currently available to management, and may vary from our actual financial position as o <br>f December 31, 2025. in Further, this presentation this preliminary has been and unaudited prepared by, estimate and is the is not responsibility a comprehensive of, our statement management. or estimate In addition, of our BDO financial USA, P. results C., our or independent financial condition registered as of public December accounting 31, 2025. firm, The has preliminary not audited, and reviewed, unaudited examined, estimate compiled, included thereto. nor applied It is agreed-upon possible that procedures we may identify with items respect that to require the preliminary us to make and adjustments unaudited estimate to the preliminary set forth herein. and unaudited Accordingly, estimate BDO USA, set forth P.C. does herein. not This express preliminary an opinion estimate or any should other not form be of viewed assurance as a with substitute respect for information financial statements and disclosure prepared is required in accordance for a more with complete generally understanding accepted accounting of our financial principles position in the United and results States of and operations is not necessarily as of December indicative 31, 2025. of the Accordingly, results to be you achieved should not in any place future undue period. reliance Additional on this preliminary and unaudited estimate.

------

![LOGO](g804277g03a03.jpg)

2025: A Breakout Year Launched PALSONIFY (paltusotine) Commercial Demonstrated Early Success Towards Market Leadership Built Fully-Integrated Pharmaceutical Company Presented Positive Phase 2 Data on Atumelnant Well-Funded well Showing Potential to into 2030 Infrastructure R&D Transform CAH Treatment Initiated Phase 3 Studies in CS and Adult CAH and Phase 1/2 in NETs Preliminary and Unaudited ~$1.4 Billion in Cash, Cash Equivalents, and Investments1 1 As of January 8, 2026; includes the net proceeds from our recent underwritten public offering of common stock that closed on January 8, 2026. CRINETICS PHARMACEUTICALS \| 3 CAH = Congenital Adrenal Hyperplasia; CS = Carcinoid Syndrome. NETs = Neuroendocrine Tumors.

------

![LOGO](g804277g04a04.jpg)

Late What's -Stage Next: Pipeline of Transformative Assets PRODUCT CANDIDATE INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATIONAL APPROVED US Patients Acromegaly (US) Paltusotine 1 36,000 (Oral SST2 Agonist) Acromegaly (EU) Paltusotine Carcinoid Syndrome 18,000-34,000² (Oral SST2 Agonist) Atumelnant Congenital Adrenal Hyperplasia ~12,000³ (Oral ACTH Antagonist) (adult) Atumelnant Congenital Adrenal Hyperplasia ~5,000³ (Oral ACTH Antagonist) (pediatric) Atumelnant Adrenocorticotropic Hormone (ACTH)- ~5,000⁴ (Oral ACTH Antagonist) Dependent Cushing's Syndrome CRN09682 NETs: 11,000-21,000⁵ Neuroendocrine Tumors (NETs) and (Non-Peptide Drug more with other SST2-Expressing Tumors Conjugate) SST2+ tumors PROMISING ASSETS FROM DISCOVERY ENGINE PARTNERING OUR TECHNOLOGY • PTH Antagonist \| Hyperparathyroidism and Other Diseases of Hypercalcemia • TSH Antagonist \| Graves' Disease, TED • SST3 Agonist \| Polycystic Kidney Disease Licensed Paltusotine for Licensee of Targeted, Licensee of CRN01941 Acromegaly Development and Nonpeptide for veterinary use • Oral GLP-1 Nonpeptide \| Diabetes, Obesity Commercialization in Japan Radiopharmaceuticals • Oral GIP Nonpeptide \| Diabetes, Obesity disease; SST: somatostatin PTH: parathyroid receptor hormone; type; ACTH: GLP adrenocorticotropic -1: glucagon-like peptide hormone; -1 receptor NETs: Neuroendocrine agonists; GIP: gastric tumors; inhibitory TSH: thyroid polypeptide; -stimulating IND: Investigational hormone; TED: New thyroid Drug eye Application; disease; ADPKD: PDUFA: Autosomal Prescription dominant Drug User polycystic Fee Act; kidney CHMP: 1 Committee US patients for only, Medicinal EU TAM Products not provided for Human . ² Patients Use. on SRL treatment for carcinoid syndrome; ³ 27K total CAH patients, but 17K requiring adjunct GC doses; ⁴ 5K patients ineligible for surgery or with tumor recurrence CRINETICS PHARMACEUTICALS \| 4 that will require pharmaceutical therapy; ⁵ Patients undergoing antitumor agent treatment for NENs; ⁶ Diagnosed patients in US

------

![LOGO](g804277g05a05.jpg)

PALSONIFY: Reflect Early Strong Success Commercial Fundamentals Patients Providers Payers Activated and Adopting with Recognizing Value Motivated Confidence Proposition >200 >125 ~50% / ~50% Enrollment Forms Unique Palsonify Reimbursed vs. Quickstart Prescribers for Newly Filled Bottles 22/22 Enrollment Forms from ~50% \| ~50% 12 Months U.S. OLE Patients Prescriber Setting Duration of Most Community \| PTC Prior Authorizations >$5M PALSONIFY 4Q2025 Net Product Revenue (Preliminary and Unaudited) Note: pharmacies Data as (Orsini of December or Biologics) 31, 2025 to initiate . An enrollment a patient form on Palsonify is an official . Pituitary document treatment containing centers both (PTCs) HCP or and community patient consent, practices submitted may also to choose CrinetiCARE to submit or an specialty CRINETICS PHARMACEUTICALS \| 5 enrollment data from specialty form to CrinetiCARE pharmacies. when Abbreviations: dispensing OLE, the Open medication -Label Extension; directly to PTC, the patient Pituitary . 81% Treatment of prior authorizations Center. have a minimum 300-day duration based on CRINETICS PHARMACEUTICALS \| 5

------

![LOGO](g804277g06a06.jpg)

Palsonify is Delivering Meaningful Patient Impact Megan David David Ashleigh Previously treated with combination of Previously treated with somatuline depot Previously treated with SRL injections, monthly and weekly injections, and is injections, then Mycapssa, and is now and is now on PALSONIFY. now on PALSONIFY. on PALSONIFY. Ashleigh is an OLE patient. "I've had some type of pain in my "For the first time in a long time, hands since before 2018. I'd been on managing my acromegaly feels, "Being on PALSONIFY has been PALSONIFY for about a week and a well, manageable. Now I don't think wonderful. I've been waiting for the half. My wife and I were getting so much about my acromegaly clinical trial to be over so I can shout ready for bed. It got quiet. And I medication. I just get up, take my it from the rooftops." looked down and said 'Baby my pills, and get ready for the day." hands don't hurt.'" CRINETICS PHARMACEUTICALS \| 6

------

![LOGO](g804277g07a07.jpg)

Paltusotine: Indication of Blockbuster Carcinoid Syndrome Potential for a Second 18-34K people Substantial with carcinoid syndrome in the U.S. Patient treated with SRLs1 Impact Patients on painful monthly SRLs injections often have breakthrough symptoms Positive Phase 2 Data Phase 3 Trial Underway Flushing frequency reduced by 63% First patient randomized in November 2025 Excess bowel movement frequency reduced by 60% 20+ sites activated Well tolerated, with safety profile consistent with other paltusotine clinical studies OLE to evaluate PFS and effect in real-world setting Preliminary investigator-assessed progression free survival (PFS) rate of 74% following one year of treatment Paltusotine is under investigation for the treatment of carcinoid syndrome. CS = Carcinoid Syndrome CRINETICS PHARMACEUTICALS \| 8 1 SEER 17 & SEER 8 (Surveillance, Epidemiology, and End Results) Health Advances analysis, data on file

------

![LOGO](g804277g08a08.jpg)

Atumelnant Glucocorticoid is Designed Use for Physiologic to Treat CAH, Replacement Reserving Only Hypothalamic-Pituitary-Adrenal (HPA) Axis in CAH Stress Hypothalamus • Atumelnant is the first and only investigational Circadian once-daily, oral MC2R antagonist in clinical testing Clock • Selectively blocks the activity of ACTH at the adrenal cortex through a single chokepoint Glucocorticoids • Decouples androgen control from GC Pituitary replacement, allowing potential for GCs to be CRF dosed at truly physiologic levels without rebound Antagonists hyperandrogenemia Atumelnant • Biochemical control of both adrenal androgens ACTH (ACTH Antagonist) and exogenous glucocorticoids for many may translate into clinical improvements A4 17-OHP Adrenal Gland Reference: 485.Abbreviations: Kim SH, ACTH, Han S, adrenocorticotrophic Zhao J, et al. Discovery hormone; of CRN04894: AVP, arginine A novel potent vasopressin; selective CRF, MC2R corticotropin-releasing antagonist. ACS Med factor; Chem MC2R, Lett. melanocortin 2024;15(4):478- type CRINETICS PHARMACEUTICALS \| 9 2 receptor; MRAP, melanocortin 2 receptor accessory protein; 17-OHP, 17-hydroxyprogesterone; 21-OH, 21-hydroxylase; GC: Glucocorticoid.

------

![LOGO](g804277g09a09.jpg)

People Atumelnant Living Vision: with CAH Healthier Hormone Levels for 2500 High A4 High A4 (A4) 2000 + + Level Normal GC High GC (ng/dL) 1500 1000 Normal A4 Androstenedione 500 + Normal High GC A4 + GC 0 5 10 15 20 25 Glucocorticoid (GC) Dose (Hydrocortisone Equivalent) (mg/m2/day) A single pill taken once a day that eliminates excess ACTH driven adrenal activation and its clinical sequalae for people struggling with Congenital Adrenal Hyperplasia Atumelnant is an investigational drug currently in Phase 3 studies for the treatment of CAH. CRINETICS PHARMACEUTICALS \| 10

------

![LOGO](g804277g10a10.jpg)

Key Rapid, Biomarker Substantial for and CAH Sustained Disease Control A4 Reductions, the GC Stable Dose, GC Dose Reduced, • All dose cohorts had substantial PM Atumelnant Dosing AM Atumelnant Dosing decreases vs. baseline, with the 1800 40 mg 80 mg 120 mg Cohort 4 80 mg magnitude of response N=10² N=11 N=6 N=8 increasing with dose (ng/dL)¹ 1600 • In Cohort 4, reducing (SE) 1400 glucocorticoid (GC) doses had no A4 1200 meaningful impact on magnitude of reduction in A4 1000 levels Serum -58% -70% • Morning dosing of atumelnant 800 -67% in Cohort 4 also had no 1,285 -80% Morning 600 1,231 1,195 discernible impact on A4 1,064 reduction Mean 400 • Additional data to be generated 560 200 455 in ongoing open-label extension 329 183 0 BL W12 BL W12 BL W12 BL W12 (EOT) (EOT) (EOT) (EOT) BL = Baseline, W12 = Week 12; EOT = End of Therapy. GC = Glucocorticoid ¹ Percentage declines shown on chart represent the means of individual percentage declines observed ² 1 participant had a missing week 12 value (taken outside time window). CRINETICS PHARMACEUTICALS \| 11

------

![LOGO](g804277g11a11.jpg)

Sustained Robust A4 with Reduction GCs Reduced Maintained to Physiologic with AM Dosing Levels and Morning Serum A4 Levels and GC Doses Over Time for Cohort 4 (80mg AM Dosing) Atumelnant GC Taper From Weeks 2-10 Stable GC Dose 14.0 A4 1500 GC Dose 7/8 Achieved 1 Mean Physiologic 13.0 GC GC Doses Serum 12.0 1000 Dose Morning 11.0 of (ng/dL) (mg/m 2 (SE) 500 10.0 Serum A4 /day) Normal Mean GC 9.0 (SE) Female ULN Male ULN 0 8.0 Baseline 2 8 12 (EOT) Week Number of Participants: Cohort 4 80 mg 10 10 9 8 .A4 = Androstenedione; GC = Glucocorticoid; EOT: End of Treatment; ULN: Upper limit of normal. 1 <11 mg/m2/day Hydrocortisone equivalents CRINETICS PHARMACEUTICALS \| 12 Atumelnant is an investigational drug currently in Phase 3 studies for the treatment of CAH.

------

![LOGO](g804277g12a12.jpg)

Adverse Atumelnant Events Continues Reported to be Well Tolerated with No Serious Phase 2 (N=38¹) OLE (N=25 to date²) (GCs reduced) Cohort 1 – 3 (N=28) (Stable GC doses) • 7 participants now have exposure ≥20 • Well tolerated, no serious adverse events and no weeks, of which 1 participant has reached treatment-related severe adverse events >40 weeks of treatment • No discontinuations • Well tolerated, no serious adverse events • 1 participant at 120 mg experienced AST/ALT increases and no treatment-related severe adverse without increases in bilirubin and with values reverting events to baseline off study drug • No discontinuations Cohort 4 (N=10¹) (GCs reduced) • No hepatic transaminase adverse events • Well tolerated, no serious adverse events and no treatment-related severe adverse events • No discontinuations due to adverse events • No hepatic transaminase adverse events • Over 750 weeks of cumulative CAH patient exposure from the Phase 2 and OLE • >200 participants have received atumelnant to date across the clinical development program, including healthy volunteer, clinical pharmacology, Cushing's and CAH studies ¹ Two subjects withdrew consent in Cohort 4. CRINETICS PHARMACEUTICALS \| 13 ² As of December 31, 2025, N=25 participants enrolled. OLE data based on limited data snapshot as of December 12,, 2025. Atumelnant is an investigational drug currently in Phase 3 studies for the treatment of CAH.

------

![LOGO](g804277g13a13.jpg)

Atumelnant: Potential for Blockbuster Therapy in CAH Substantial ~12K ~5K Currently Living with Patient Adults Children CAH in the U.S. Impact Positive Phase 2 Data Phase 3 Program Underway Rapid and sustained mean A4 reductions of up to First patient randomized in December 2025 80% as soon as 2 weeks and sustained at 12 weeks across all cohorts Pediatric trial to initiate in 1H2026 A4 reductions maintained in Cohort 4 while GC Phase 2 OLE ongoing to gather incremental doses reduced to physiologic levels in 7 of 8 patients data on longer duration of treatment, and Well tolerated, with favorable benefit/risk profile will include patients rolling over from Phase 3

------

![LOGO](g804277g14a14.jpg)

Drug CRN09682: Conjugate First Candidate Platform for from SST2-Expressing Crinetics' Nonpeptide Tumors Differentiation vs. Current Modalities • Non-cytotoxic when linked Payload • Highly potent when free Anticancer Agents • Interchangeable payload for (Chemotherapies, PROTAC) future development X Not tumor specific X Unfavorable PK/ADME Linker X Narrow therapeutic index • Stable in plasma • Cleaved intracellularly Antibody-Drug Conjugate Ligand • Selective nonpeptide SST2 agonist X Long half-life • High affinity and selectivity X Poor tumor penetration • Optimized internalization X Nonspecific uptake • Low molecular weight • Traditional chemical synthesis • Designed for straightforward Radioligand Therapies substitution with other GPCR-CRN09682 targeting small molecules X Limited number of cycles X Radionuclide supply Nonpeptide drug conjugate X Treatment logistics targeting SST2 receptors X Radiation safety MMAE: monomethyl auristatin E; tubulin inactivator; PROTAC: Proteolysis-targeting chimeras; PK: pharmacokinetics; ADME: Absorption, Distribution, Metabolism, and Excretion CRINETICS PHARMACEUTICALS \| 15

------

![LOGO](g804277g15a15.jpg)

Tumors CRN09682: and Potential Other SST2+ Blockbuster Tumors for Neuroendocrine ~11-21K people And even more Substantial treated with with other SST2+ Patient tumors (U.S.) Impact antitumor agents for NETs1 (U.S.) Promising Preclinical Data Phase 1/2 Program Underway Selectively delivered MMAE into SST2+ SCLC tumor First patient dosed in November 2025 model with minimal systemic exposure to free MMAE Phase 1 dose escalation study with Bayesian Induced rapid tumor regression in SCLC preclinical optimal interval design cell-derived tumor model in a dose-dependent Phase 2 dose expansion study in manner SST2+ expressing neuroendocrine tumors, SCLC and other neuroendocrine carcinomas, and other solid tumors MMAE: monomethyl auristatin E; NET: Neuroendocrine tumor; SCLC: small cell lung cancer); SSTR: somatostatin receptor CRINETICS PHARMACEUTICALS \| 16 1 SEER 17 & SEER 8 (Surveillance, Epidemiology, and End Results), Health Advances analysis, data on file.

------

![LOGO](g804277g16a16.jpg)

Vision 2030: Emerging as the Premier Endocrinology Business Sustainable Growth Funded by Revenue 2 Marketed Products 4 Approved Indications 7+ Clinical Pipeline Candidates Pipeline Expansion Fueled by Internal Innovation The vision for 2030 is aspirational and subject to significant risks, including the successful completion of ongoing and CRINETICS PHARMACEUTICALS \| 17 future clinical programs, regulatory review and approval by relevant authorities, and market conditions.

------

![LOGO](g804277g17a17.jpg)

THANK YOU CRINETICS PHARMACEUTICALS \| 18 CRINETICS PHARMACEUTICALS \| Atumelnant is an investigational drug currently in Phase 3 studies for the treatment of CAH. 14 CRINETICS PHARMACEUTICALS \| 6 CRINETICS PHARMACEUTICALS \| 2 Livingw

------

![LOGO](g804277g18a18.jpg)

ith Acromegaly